See more : Enphys Acquisition Corp. (NFYS) Income Statement Analysis – Financial Results
Complete financial analysis of Vericel Corporation (VCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vericel Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Thule Group AB (publ) (THLPF) Income Statement Analysis – Financial Results
- Shanshan Brand Management Co., Ltd. (1749.HK) Income Statement Analysis – Financial Results
- University Bancorp, Inc. (UNIB) Income Statement Analysis – Financial Results
- Samsonite International S.A. (1910.HK) Income Statement Analysis – Financial Results
- ICICI Prudential Life Insurance Company Limited (ICICIPRULI.BO) Income Statement Analysis – Financial Results
Vericel Corporation (VCEL)
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 197.52M | 164.37M | 156.18M | 124.18M | 117.85M | 90.86M | 63.92M | 54.38M | 51.17M | 28.80M | 19.00K | 21.00K | 18.00K | 89.00K | 182.00K | 522.00K | 685.00K | 863.00K | 909.00K | 1.30M | 844.00K | 877.00K | 899.00K | 1.15M | 881.00K | 249.00K | 400.00K | 1.60M |
Cost of Revenue | 61.94M | 54.58M | 50.16M | 39.95M | 37.57M | 32.16M | 30.35M | 28.31M | 26.47M | 17.29M | 4.00K | 6.00K | 4.00K | 34.00K | 112.00K | 56.00K | 29.00K | 11.00K | 148.00K | 280.00K | 893.00K | 202.00K | 13.00K | 926.00K | 6.00K | 0.00 | -500.00K | 9.60M |
Gross Profit | 135.58M | 109.79M | 106.03M | 84.23M | 80.28M | 58.70M | 33.57M | 26.08M | 24.70M | 11.50M | 15.00K | 15.00K | 14.00K | 55.00K | 70.00K | 466.00K | 656.00K | 852.00K | 761.00K | 1.02M | -49.00K | 675.00K | 886.00K | 224.00K | 875.00K | 249.00K | 900.00K | -8.00M |
Gross Profit Ratio | 68.64% | 66.80% | 67.88% | 67.83% | 68.12% | 64.60% | 52.52% | 47.95% | 48.27% | 39.95% | 78.95% | 71.43% | 77.78% | 61.80% | 38.46% | 89.27% | 95.77% | 98.73% | 83.72% | 78.49% | -5.81% | 76.97% | 98.55% | 19.48% | 99.32% | 100.00% | 225.00% | -500.00% |
Research & Development | 21.04M | 19.94M | 16.29M | 13.02M | 30.39M | 13.60M | 12.94M | 15.30M | 18.89M | 21.26M | 15.10M | 26.03M | 21.33M | 12.66M | 11.29M | 15.25M | 11.44M | 9.48M | 7.21M | 6.29M | 5.65M | 5.43M | 4.98M | 6.29M | 10.87M | 15.50M | 13.40M | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.01M | 35.61M | 27.39M | 22.48M | 13.77M | 5.88M | 7.75M | 0.00 | 5.20M | 4.95M | 6.44M | 8.68M | 9.10M | 5.97M | 5.39M | 4.02M | 3.53M | 2.48M | 3.36M | 2.84M | 2.86M | 2.00M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 121.00M | 106.90M | 97.59M | 68.84M | 61.14M | 49.01M | 35.61M | 27.39M | 22.48M | 13.77M | 5.88M | 7.75M | 7.72M | 5.20M | 4.95M | 6.44M | 8.68M | 9.10M | 5.97M | 5.39M | 4.02M | 3.53M | 2.48M | 3.36M | 2.84M | 2.86M | 2.00M | 2.10M |
Other Expenses | 0.00 | 95.00K | 52.00K | -13.00K | -20.00K | -31.00K | -92.00K | -10.00K | 47.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.21M | 5.64M | 5.64M | 0.00 | 325.00K | 0.00 | 0.00 | 500.00K | 400.00K |
Operating Expenses | 142.04M | 126.85M | 113.88M | 81.86M | 91.53M | 62.61M | 48.55M | 42.68M | 41.37M | 35.04M | 20.98M | 33.78M | 29.05M | 17.86M | 16.24M | 21.69M | 20.13M | 18.59M | 13.18M | 11.68M | 9.66M | 8.96M | 7.47M | 9.98M | 13.71M | 18.36M | 15.90M | 2.50M |
Cost & Expenses | 203.98M | 181.42M | 164.04M | 121.81M | 129.10M | 94.77M | 78.91M | 70.99M | 67.84M | 52.33M | 20.98M | 33.78M | 29.06M | 17.89M | 16.35M | 21.74M | 20.15M | 18.60M | 13.33M | 11.96M | 10.56M | 9.16M | 7.48M | 10.90M | 13.71M | 18.36M | 15.40M | 12.10M |
Interest Income | 4.63M | 1.34M | 224.00K | 691.00K | 1.61M | 897.00K | 14.00K | 8.00K | 36.00K | 24.00K | 16.00K | 50.00K | 53.00K | 115.00K | 296.00K | 1.17M | 1.26M | 594.00K | 594.00K | 169.00K | 134.00K | 342.00K | 364.00K | 364.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 600.00K | 366.00K | 4.00K | 6.00K | 8.00K | 1.73M | 1.11M | 314.00K | 9.00K | 6.00K | 11.00K | 12.00K | 10.00K | 40.00K | 73.00K | 73.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 4.63M | 8.20M | 7.39M | 6.83M | 4.53M | 1.43M | 1.61M | 1.89M | 1.59M | 752.00K | 489.00K | 649.00K | 647.00K | 592.00K | 704.00K | 351.00K | -47.00K | 191.00K | 99.00K | 125.00K | 119.00K | 126.00K | 102.00K | 325.00K | 226.00K | 377.00K | 500.00K | 400.00K |
EBITDA | 2.86M | -11.64M | -4.61M | 9.88M | -5.13M | -4.98M | -14.57M | -17.37M | -14.74M | -19.16M | -15.12M | -28.81M | -19.01M | -30.15M | -17.80M | -15.47M | -21.22M | -19.47M | -17.73M | -12.42M | -10.36M | -9.71M | -8.16M | -6.48M | -9.43M | -12.62M | -17.75M | -14.50M |
EBITDA Ratio | 1.45% | -9.50% | -4.85% | 2.46% | -8.19% | -3.35% | -23.56% | -30.54% | -32.42% | -81.65% | -107,678.95% | -157,433.33% | -209,566.67% | -19,339.33% | -8,497.25% | -3,997.70% | -2,842.19% | -2,032.68% | -1,356.44% | -808.91% | -1,136.73% | -929.87% | -720.47% | -819.91% | -1,571.28% | -7,120.48% | -3,800.00% | -675.00% |
Operating Income | -6.46M | -17.06M | -7.85M | 667.00K | -11.25M | -3.91M | -14.98M | -19.25M | -16.67M | -23.53M | -20.96M | -33.76M | -29.04M | -17.80M | -16.17M | -21.22M | -19.47M | -17.73M | -12.42M | -10.66M | -9.71M | -8.28M | -6.58M | -9.75M | -12.83M | -18.11M | -15.00M | -10.50M |
Operating Income Ratio | -3.27% | -10.38% | -5.03% | 0.54% | -9.55% | -4.30% | -23.44% | -35.39% | -32.58% | -81.73% | -110,336.84% | -160,761.90% | -161,333.33% | -20,004.49% | -8,884.07% | -4,064.94% | -2,842.19% | -2,054.81% | -1,366.01% | -818.51% | -1,150.83% | -944.24% | -731.81% | -848.17% | -1,456.53% | -7,271.89% | -3,750.00% | -656.25% |
Total Other Income/Expenses | 4.10M | 1.07M | 272.00K | 672.00K | 1.59M | -4.23M | -2.30M | -321.00K | 331.00K | 3.61M | 5.34M | 4.29M | 9.37M | -20.37M | 1.86M | 223.00K | 1.09M | 1.88M | 1.26M | 606.00K | 169.00K | 134.00K | -1.11M | 364.00K | 1.24M | 0.00 | 3.85M | 5.20M |
Income Before Tax | -2.37M | -15.99M | -7.58M | 3.04M | -9.67M | -8.14M | -17.29M | -19.57M | -16.34M | -19.92M | -15.62M | -29.47M | -19.71M | -17.73M | -15.95M | -20.13M | -16.48M | -11.81M | -12.41M | -10.49M | -9.58M | -7.94M | -9.39M | -9.39M | -11.60M | 0.00 | -14.30M | -9.80M |
Income Before Tax Ratio | -1.20% | -9.73% | -4.85% | 2.45% | -8.20% | -8.96% | -27.04% | -35.98% | -31.93% | -69.18% | -82,221.05% | -140,352.38% | -109,505.56% | -19,920.22% | -8,761.54% | -3,856.90% | -2,405.11% | -1,368.60% | -1,364.69% | -805.53% | -1,134.95% | -905.25% | -1,044.49% | -816.52% | -1,316.12% | 0.00% | -3,575.00% | -612.50% |
Income Tax Expense | 814.00K | 721.00K | -111.00K | 180.00K | -1.76M | 3.36M | 1.12M | 2.64M | -257.00K | -3.60M | -5.34M | -4.25M | -18.71M | -115.00K | -296.00K | -1.09M | -1.83M | -1.26M | -618.00K | -169.00K | -134.00K | -342.00K | -653.00K | -364.00K | -3.04M | -874.00K | -1.40M | -1.30M |
Net Income | -3.18M | -16.71M | -7.47M | 2.86M | -7.91M | -8.14M | -17.29M | -19.57M | -16.34M | -19.92M | -15.62M | -29.47M | -19.67M | -17.73M | -15.95M | -20.13M | -17.59M | -16.48M | -11.81M | -10.49M | -9.58M | -7.94M | -5.93M | -9.39M | -11.03M | -17.23M | -14.30M | -9.90M |
Net Income Ratio | -1.61% | -10.17% | -4.78% | 2.31% | -6.71% | -8.96% | -27.04% | -35.98% | -31.93% | -69.18% | -82,221.05% | -140,352.38% | -109,266.67% | -19,920.22% | -8,761.54% | -3,856.90% | -2,568.47% | -1,909.04% | -1,299.34% | -805.53% | -1,134.95% | -905.25% | -659.18% | -816.52% | -1,251.76% | -6,920.88% | -3,575.00% | -618.75% |
EPS | -0.07 | -0.35 | -0.16 | 0.06 | -0.18 | -0.20 | -0.52 | -0.85 | -0.69 | -1.71 | -5.18 | -14.31 | -10.19 | -14.34 | -17.84 | -24.95 | -23.55 | -24.79 | -20.20 | -22.77 | -30.06 | -30.16 | -27.86 | -64.36 | -115.01 | -206.34 | -203.20 | -171.20 |
EPS Diluted | -0.07 | -0.35 | -0.16 | 0.06 | -0.18 | -0.20 | -0.52 | -0.85 | -0.69 | -1.71 | -5.18 | -14.31 | -10.19 | -14.34 | -17.84 | -24.95 | -23.55 | -24.79 | -20.20 | -22.77 | -30.06 | -30.16 | -27.86 | -64.36 | -115.01 | -206.34 | -203.20 | -171.20 |
Weighted Avg Shares Out | 47.59M | 47.13M | 46.47M | 45.22M | 44.18M | 40.24M | 33.35M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 1.93M | 1.24M | 893.85K | 807.00K | 747.02K | 664.46K | 584.63K | 460.64K | 318.65K | 263.26K | 212.69K | 145.90K | 95.89K | 83.52K | 70.37K | 57.83K |
Weighted Avg Shares Out (Dil) | 47.59M | 47.13M | 46.47M | 47.28M | 44.18M | 40.24M | 33.36M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 1.93M | 1.24M | 893.85K | 807.00K | 747.02K | 664.46K | 584.63K | 460.64K | 318.65K | 263.26K | 212.69K | 145.90K | 95.89K | 83.52K | 70.37K | 57.83K |
Vericel Corporation (VCEL) Q3 2023 Earnings Call Transcript
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel to Present at the Stephens Annual Investment Conference
Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
Top Medical Stocks to Buy Amid Recent Market Volatility
New Strong Buy Stocks for October 23rd
New Strong Buy Stocks for October 19th
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
Source: https://incomestatements.info
Category: Stock Reports